

Online Resource 2

A Phase I Study of Enfortumab Vedotin in Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Investigational New Drugs

Shunji Takahashi¹, Motohide Uemura², Tomokazu Kimura³, Yoshihide Kawasaki⁴, Atsushi Takamoto⁵, Akito Yamaguchi⁶, Amal Melhem-Bertrandt⁷, Elaina M. Gartner⁸, Takashi Inoue⁹, Rio Akazawa⁹, Takeshi Kadokura⁹, Toshiki Tanikawa¹⁰

¹The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; ²Osaka University Hospital, Osaka, Japan; ³University of Tsukuba Hospital, Tsukuba, Japan; ⁴Tohoku University Hospital, Sendai, Japan; ⁵Okayama University Hospital, Okayama, Japan; ⁶Harasanshin Hospital, Fukuoka, Japan; ⁷Astellas Pharma Global Development, Northbrook, IL, USA; ⁸Seattle Genetics, Seattle, WA, USA; ⁹Astellas Pharma, Inc., Tokyo, Japan; ¹⁰Niigata Cancer Center Hospital, Niigata, Japan

Corresponding author:

Shunji Takahashi, MD

E-mail: s.takahashi-chemotherapy@jfcr.or.jp

Defined Kaplan-Meier Plot Censorship Criteria

The following were censorship criteria for duration of response (DoR):

- If patient had neither PD nor death, the DoR was censored at last radiological tumor assessment date on or prior to the cutoff date, or at the date of first confirmed complete response/partial response if no subsequent radiological assessment was available
- If patient took any new anticancer therapy before any PD event or death, the DoR was censored at the date of last tumor assessment date prior to the date of new anticancer therapy

The following were censorship criteria for progression-free survival (PFS):

- If patient had neither PD nor death, the PFS was censored at the last radiological tumor assessment date
- If patient took any new anticancer therapy before any PD event or death, the PFS was censored at the date of the last tumor assessment during study period prior to the date of new anticancer therapy; in the case that patient did not have postbaseline tumor assessment, the PFS was censored at the date of first dose